Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deucrictibant - Pharvaris

Next Previous
Search
Drug Profile

Deucrictibant - Pharvaris

Alternative Names: PHA-022121; PHA-121; PHVS 416; PHVS 719; PHVS416 - soft capsule formulation; PHVS719 - XR tablet

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharvaris
  • Class Acetamides; Benzene derivatives; Ethers; Halogenated hydrocarbons; Organic deuterium compounds; Quinolines; Skin disorder therapies; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema; Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Angioedema
  • Clinical Phase Unknown Acquired angioedema

Most Recent Events

  • 01 Apr 2025 Deucrictibant - Pharvaris receives Orphan Drug status for Hereditary angioedema in European Union
  • 03 Mar 2025 Efficacy and adverse evet data from the phase II HAE CHAPTER-1 trial in Hereditary angioedema released by Pharvaris
  • 01 Feb 2025 Pharvaris initiates enrolment in its phase-III CHAPTER-4 clinical trial in Hereditary angioedema (In adults, In adolescents, In the elderly) in United Kingdom, Hong Kong (PO) (NCT06679881)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top